Liangang Liu

Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus

Peter Schäfer, Ying Ye, Lei Wu et al. · Annals of the Rheumatic Diseases · 2018 · 77 citations · Full text

Population pharmacokinetics of pomalidomide

Yan Li, Yejun Xu, Liangang Liu et al. · The Journal of Clinical Pharmacology · 2015 · 46 citations · Full text

Urology, Healthy Subjects, Medicine +10

Pomalidomide: Evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects

Claudia Kasserra, Mahmoud Assaf, Matthew Hoffmann et al. · The Journal of Clinical Pharmacology · 2014 · 40 citations

Medicinal Chemistry, Healthy Subjects, Biochemistry +14

No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers

Nianhang Chen, Josephine Reyes, Liangang Liu et al. · Cancer Chemotherapy and Pharmacology · 2014 · 30 citations · Full text

First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator

Ying Ye, Allison Gaudy, Peter Schäfer et al. · Clinical Pharmacology in Drug Development · 2020 · 28 citations · Full text